DeepMatter Group PLC - company which focuses on digitising chemistry - Says one of its wholly owned subsidiaries has entered into a multi-year, limited-use data licensing agreement with the Life Science business of Merck KGaA to provide proprietary chemical structure and reaction data content to Merck's selected application. "We are delighted to have entered into this license with Merck, a company dedicated to making research and biotech simpler, faster and safer," says DeepMatter Chief Executive Mark Warne.
DeepMatter current stock price: 2.32 pence, down 1.1% on Wednesday
Year-to-date change: up 16%
Merck current stock price: EUR142.70, down 4.1% on Wednesday
Year-to-date change: up 1.7%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
